SCHEMBL1623907

SCHEMBL1623907

CCc1ccc(-c2ccc(OC)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.61
IDO1 P14902 3/20 0.54
ESR2 Q92731 1/20 0.54
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 1/20 0.51
AGXT P21549 2/20 0.50
LTA4H P09960 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
TP53 P04637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17614860 1.00 MAOB (0.61) MAOBIDO1ESR2CA12CA1
SCHEMBL13674501 0.94 MAOB (0.55) MAOBIDO1ESR2CA12CA1
SCHEMBL14380144 0.94 MAOB (0.55) MAOBIDO1ESR2CA12CA1
SCHEMBL30878 0.93 CA12 (0.61) MAOBIDO1CA12CA1CA2
Ammonia Solution, Strong SCHEMBL266020 0.90 IDO1 (0.58) MAOBIDO1CA12CA1CA2
Bromide SCHEMBL28187052 0.90 IDO1 (0.58) MAOBIDO1CA12CA1CA2
SCHEMBL18674330 0.90 MAOB (0.52) MAOBIDO1ESR2CA12CA1
SCHEMBL12533874 0.90 MAOB (0.52) MAOBIDO1ESR2CA12CA1
Bromide SCHEMBL25274321 0.88 IDO1 (0.56) MAOBIDO1CA12CA1CA2
Ethyne SCHEMBL27462853 0.88 IDO1 (0.56) MAOBIDO1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118324596-A Synthesis method of biaryl compound 新疆大学 2024-07-12 CN disclosed
US-12024665-B2 Polymer-stabilized liquid crystal composition and use thereof BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) 2024-07-02 US disclosed
US-12024665-B2 Polymer-stabilized liquid crystal composition and use thereof BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) 2024-07-02 US disclosed
US-20230265345-A1 LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND AND APPLICATION OF LIQUID CRYSTAL COMPOSITION BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) 2023-08-24 US disclosed
US-20220389320-A1 POLYMER-STABILIZED LIQUID CRYSTAL COMPOSITION AND USE THEREOF BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD (CN) 2022-12-08 US disclosed
WO-2022129432-A1 THERMOPLASTIC COMPOSITES MATERIALS SOLVAY SPECIALTY POLYMERS USA, LLC (US) 2022-06-23 WO disclosed
WO-2021260054-A2 SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW SAPREME TECHNOLOGIES B.V. (NL) 2021-12-30 WO disclosed
US-11162028-B2 Liquid crystal composition and application thereof JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) 2021-11-02 US disclosed
WO-2021119249-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2021-06-17 WO disclosed
US-20210017450-A1 LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE HAVING SAME JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) 2021-01-21 US disclosed
US-7258903-B2 Fast switching liquid crystal compositions for use in bistable liquid crystal devices MERCK PATENT GMBH (DE) 2007-08-21 US disclosed
US-20070176144-A1 Liquid crystal composition for bistable liquid crystal devices MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2007-08-02 US disclosed
US-20070111994-A1 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-05-17 US disclosed
US-20070111994-A1 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-05-17 US disclosed
WO-2007053725-A2 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-05-10 WO disclosed
EP-1570025-B1 LIQUID CRYSTAL COMPOSITION FOR USE IN BISTABLE LIQUID CRYSTAL DEVICES MERCK PATENT GMBH (DE) 2007-04-11 EP disclosed
US-5914213-A MIXTURE; THERMAL DECOMPOSITION; IMAGE MEDIUM POLAROID CORPORATION (US) 1999-06-22 US disclosed
US-4012434-A Nematic compounds and mixtures MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-03-15 US disclosed
US-4002670-A 4'-ALKOXY OR ALKYL PHENYL ESTERS OF 4-ALKYL OR ALKOXY BENZOIC ACIDS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-01-11 US disclosed
US-4001137-A Nematic compounds and mixtures MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111994-A1 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties BAD, GABRA5, GABRB1 MAOB 2222/4885IDO1 423/4885ESR2 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.